Main Industry
Biotechnology
Main Product/Service
The immunogens used by IReal Biotechnology Co., Ltd. for antibody production are all short peptide fragments. Using rabbits as hosts, the developed antibodies combine the high sensitivity of rabbit polyclonals with the high specificity of mouse monoclonals. All antibodies are designed, developed, and quality-validated in-house. We provide commonly used antibodies for currently popular research fields, including EMT markers, Apoptosis, ER stress, Cell Cycle, Autophagy, and Neuroscience, as well as a customized antibody service platform. Antibody applications include: Western Blots (WB), Immunohistochemistry (IHC), Enzyme-Linked Immunosorbent Assays (ELISA), Flow Cytometry (FACS), and Immunoprecipitation (IP).
The content above was translated by Ai
Founded Year
2018
Unified Business No.
42966124
Status
Active
Number of Employees
0
Total Paid-in
Capital
42,000,000 (NT$)
Location of Company
Taiwan
, Hsinchu City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
IReal Biotechnology Co., Ltd. was founded in 2018 and is dedicated to the research, development, and sale of high-quality antibodies for scientific research and clinical diagnosis. Utilizing a next-generation rabbit monoclonal antibody production platform, the company selects and develops targets with potential for diagnostic reagents and antibody drugs to enter the high-sensitivity diagnostic reagent and therapeutic antibody market. Supported by strategic alliance development or licensing, the company aims to bring its products to the preclinical stage.
The content above was translated by Ai
